首页> 美国卫生研究院文献>Journal of Clinical Medicine >Short-Term Results of Ocriplasmin versus Prompt Vitrectomy for Macular Hole. Which Performs Better?
【2h】

Short-Term Results of Ocriplasmin versus Prompt Vitrectomy for Macular Hole. Which Performs Better?

机译:黄斑瘤素的短期结果与促进玻璃孔的促进玻璃孔。哪个表现更好?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this retrospective study, we compared the anatomical and functional changes in patients with vitreomacular traction associated with macular holes between the following groups: (1) Patients who were treated with a single intravitreal injection of ocriplasmin (the OCRIALONE group); (2) those who failed the ocriplasmin treatment and underwent vitrectomy one month later (the OCRIVIT group); and (3) patients who directly underwent par plana vitrectomy (VITREALONE group). A total of 38 patients, 19 in the OCRIALONE group + OCRIVIT group (seven and 12 patients, respectively) and 19 in the VITREALONE group with focal vitreomacular adhesion associated with macular holes were evaluated with spectral domain optical coherence tomography. Functional examinations included best-corrected visual acuity (BCVA) and microperimetry analysis. Visual function changes were compared between the OCRIALONE group + OCRIVIT group and VITREALONE group up to three months. Furthermore, a subgroup analysis compared the OCRIVIT group and the VITREALONE group. BCVA values and the mean retinal sensitivity showed statistically significant improvement in all groups (p < 0.001). Specifically, the retinal sensitivity values at the end of the follow-up were significantly higher in the OCRIALONE group + OCRIVIT group than in the VITREALONE group. These functional findings were also confirmed when the statistical analysis was conducted between the OCRIVIT group and the VITREALONE group. Although the OCRIALONE group + OCRIVIT group exhibited faster retinal thinning than the VITREALONE group (p = 0.006), the analysis of the OCRIVIT group versus the VITREALONE group did not show any statistically significant difference. The better functional results and similar anatomical findings suggest that ocriplasmin can be used as a first-line treatment, and that prompt pars plana vitrectomy as primary surgery does not provide better outcomes in comparison with pars plana vitrectomy after ocriplasmin injection.
机译:在这项回顾性研究中,我们比较了与以下组之间的玻璃体孔相关的玻璃体术患者的解剖学和功能变化:(1)用单一玻璃肌醇注射OCRIPLASMIN治疗的患者(OCrialone组); (2)减少OCRIPLASMIN治疗和一个月后的玻璃体切除术(OCRIVIT组)的人; (3)直接接受Para玻璃体切除术(Vitealone Group)的患者。共有38名患者,19例在炎症组+ OCrivit组(分别为七和12名患者)和19中,vitrealone组,具有焦点玻璃孔与黄斑孔的粘附性,采用光谱畴光学相干断层扫描。功能检查包括最佳校正的视力(BCVA)和微型仪分析。在Ocrialone Group + Ocrivit Group和ViTrealone Group之间比较了视觉功能的变化,长达三个月。此外,亚组分析比较了Ocrivit组和vitrieLone组。 BCVA值和平均视网膜敏感性显示所有基团的统计学显着改善(P <0.001)。具体而言,在紫外线组+ Ocrivit组的后续后续结束时的视网膜敏感值显着高于vitrieLone组。当在Ocrivit组和vitrealone组之间进行统计分析时,还确认了这些功能性发现。虽然Ocrialone组+ Ocrivit组比Vitivone Group(p = 0.006)表现出更快的视网膜稀疏,但随后对vitrieLone组的分析没有显示任何统计学意义。更好的功能结果和类似的解剖结果表明,OCRIPLASMIN可以用作一线治疗,并且随着初级手术的促销标准玻璃体切除术与ocriplasmin注射后的PARS Plana Vectomy相比,Plana Vitecomy不提供更好的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号